ALEMBIC PHARMACEUTICALS
Quarterly Results Analysis [Mar2024]
ALEMBIC PHARMACEUTICALS Quarterly Results
Consolidated | Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,517 Cr | ₹1,631 Cr | ₹1,595 Cr | ₹1,486 Cr | ₹1,406 Cr | ₹1,509 Cr | ₹1,475 Cr | ₹1,262 Cr |
Expenses | ₹1,257 Cr | ₹1,364 Cr | ₹1,387 Cr | ₹1,287 Cr | ₹1,194 Cr | ₹1,260 Cr | ₹1,242 Cr | ₹1,247 Cr |
Operating Income | ₹260 Cr | ₹266 Cr | ₹208 Cr | ₹199 Cr | ₹212 Cr | ₹249 Cr | ₹233 Cr | ₹15 Cr |
Other Income | ₹4 Cr | ₹3 Cr | ₹10 Cr | ₹12 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
Interest | ₹11 Cr | ₹15 Cr | ₹16 Cr | ₹14 Cr | ₹14 Cr | ₹15 Cr | ₹12 Cr | ₹9 Cr |
Depreciation | ₹69 Cr | ₹69 Cr | ₹68 Cr | ₹66 Cr | ₹74 Cr | ₹67 Cr | ₹68 Cr | ₹67 Cr |
Profit Before Tax | ₹183 Cr | ₹185 Cr | ₹135 Cr | ₹130 Cr | ₹125 Cr | ₹168 Cr | ₹153 Cr | ₹-60 Cr |
Profit After Tax | ₹179 Cr | ₹181 Cr | ₹137 Cr | ₹121 Cr | ₹161 Cr | ₹136 Cr | ₹135 Cr | ₹-59 Cr |
EPS | ₹9.07 | ₹9.18 | ₹6.95 | ₹6.14 | ₹7.76 | ₹6.20 | ₹6.78 | ₹-3.35 |
Industry Peers & Returns | 1W | 1M | 1Y |
ALEMBIC PHARMACEUTICALS | 0.3% | 3.9% | 71.6% |
SUN PHARMACEUTICAL INDUSTRIES | -0.9% | 0.9% | 62.6% |
CIPLA | 3.5% | 4.2% | 51.8% |
DR REDDYS LABORATORIES | -1% | -2.4% | 28.4% |
ZYDUS LIFESCIENCES | 12.2% | 18% | 103.8% |
DIVIS LABORATORIES | 0.8% | 5.6% | 19.3% |
MANKIND PHARMA | -6.1% | -11.9% | 54.1% |
TORRENT PHARMACEUTICALS | 2.9% | 6.2% | 66.2% |
LUPIN | 1.5% | 4.2% | 109.2% |
ALEMBIC PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -6.97 % |
Y-o-Y | 7.86 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹1,517 Cr | -6.97 | |
Dec2023 | ₹1,631 Cr | 2.23 | |
Sep2023 | ₹1,595 Cr | 7.32 | |
Jun2023 | ₹1,486 Cr | 5.67 | |
Mar2023 | ₹1,406 Cr | -6.80 | |
Dec2022 | ₹1,509 Cr | 2.31 | |
Sep2022 | ₹1,475 Cr | 16.87 | |
Jun2022 | ₹1,262 Cr | - |
ALEMBIC PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -2.37 % |
Y-o-Y | 22.54 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹260 Cr | -2.37 | |
Dec2023 | ₹266 Cr | 27.91 | |
Sep2023 | ₹208 Cr | 4.81 | |
Jun2023 | ₹199 Cr | -6.38 | |
Mar2023 | ₹212 Cr | -14.69 | |
Dec2022 | ₹249 Cr | 6.88 | |
Sep2022 | ₹233 Cr | 1,488.67 | |
Jun2022 | ₹15 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 4.90 % |
Y-o-Y | 13.59 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 17.14% | 4.90 | |
Dec2023 | 16.34% | 25.11 | |
Sep2023 | 13.06% | -2.32 | |
Jun2023 | 13.37% | -11.40 | |
Mar2023 | 15.09% | -8.43 | |
Dec2022 | 16.48% | 4.44 | |
Sep2022 | 15.78% | 1,260.34 | |
Jun2022 | 1.16% | - |
ALEMBIC PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -1.05 % |
Y-o-Y | 10.90 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹179 Cr | -1.05 | |
Dec2023 | ₹181 Cr | 31.68 | |
Sep2023 | ₹137 Cr | 13.63 | |
Jun2023 | ₹121 Cr | -25.10 | |
Mar2023 | ₹161 Cr | 18.84 | |
Dec2022 | ₹136 Cr | 0.39 | |
Sep2022 | ₹135 Cr | Positive | |
Jun2022 | ₹-59 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 6.32 % |
Y-o-Y | 2.79 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 11.77 % | 6.32 | |
Dec2023 | 11.07 % | 28.87 | |
Sep2023 | 8.59 % | 5.79 | |
Jun2023 | 8.12 % | -29.08 | |
Mar2023 | 11.45 % | 27.51 | |
Dec2022 | 8.98 % | -1.86 | |
Sep2022 | 9.15 % | Positive | |
Jun2022 | -4.65 % | - |
ALEMBIC PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -1.20 % |
Y-o-Y | 16.88 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹9.07 | -1.20 | |
Dec2023 | ₹9.18 | 32.09 | |
Sep2023 | ₹6.95 | 13.19 | |
Jun2023 | ₹6.14 | -20.88 | |
Mar2023 | ₹7.76 | 25.16 | |
Dec2022 | ₹6.2 | -8.55 | |
Sep2022 | ₹6.78 | Positive | |
Jun2022 | ₹-3.35 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD